Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
February 7, 2023 4:01 PM ESTFull year product revenue of $8.93 billion, an 18% increase compared to full year 2021
Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021
Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion
Exa-cel regulatory submissions validated in the EU and U.K.; U.S. rolling BLA submission underway
Advancing broad and diverse clinical pipeline, with multiple clinical milestones expected in 2023
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the... More
